Creative Medical Technology Holdings, Inc. Prices $16 Million Public Offering and Uplisting to the Nasdaq Capital Market

About this update from Creative Medical Technology Holdings, Inc.

[{"type":"text","content":"PHOENIX, Dec. 3, 2021 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (the \"Company\") (NASDAQ: CELZ), a commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced the pricing of the underwritten public offering of 3,875,000 shares of common stock and accompanying warrants to purchase up to 3,875,000 shares of common stock at a combined public offering price of $4.13. The warrants have a per share exercise price of $4.13, are exercisable immediately, and expire five years from the date of issuance. The aggregate gross proceeds from the offering are expected to total approximately $16 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company and without giving effect to proceeds from any subsequent exercise of warrants.\n\n \n \n \n \n \n \n\n \nAs a result of the offering, the Company's common stock will become listed on the Nasdaq Capital Market and will trade under the ticker symbol \"CELZ\" beginning December 3, 2021. The offering is expected to close on or about December 7, 2021, subject to customary closing conditions. In addition, the Company has granted to the underwriters of the offering a 45-day option to purchase up to 581,250 additional shares and/or additional warrants to purchase up to 581,250 shares of common stock to cover over-allotments, if any.\nRoth Capital Partners is acting as sole manager for the offering.\nThe securities described above are being sold by the Company pursuant to a registration statement on Form S-1 (Registration No. 333-259834) that was previously filed by the Company with the Securities and Exchange Commission (the \"SEC\") and declared effective on December 2, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. \nThe offering is being made only by means of the written prospectus forming part of the effective registration statement. Electronic copies of the accompanying prospectus may be obtained, when available, by contacting Ro...

More updates from Creative Medical Technology Holdings, Inc.